Results 71 – 80 of 240 for copd foundation (0.04 seconds)

First patients dosed in three dermatology trials evaluating Fasenra in bullous pemphigoid, atopic dermatitis and chronic spontaneous urticaria

anticipated 2022+ Chronic obstructive pulmonary disease (COPD) RESOLUTE: A phase III trial to evaluate the efficacy and safety of benralizumab in ...

แอสตร้าเซนเนก้า ประเทศไทย ร่วมกับ เขตสุขภาพที่ 11 กระทรวงสาธารณสุข เดินหน้าโครงการ Healthy Lung Thailand ส่งมอบอุปกรณ์ตรวจสมรรถภาพปอด เพื่อเพิ่มศักยภาพการตรวจรักษาโรคหืดและปอดอุดกั้นเรื้อรัง

โดยในแต่ละปีมีผู้ป่วยที่เสียชีวิตจากโรคหืดกว่า 2,000 ราย ส่วนโรคปอดอุดกั้นเรื้อรัง (COPD) เป็นหนึ่งในสาเหตุของการเสียชีวิตลำดับต้น ๆ ของประชากรไทย ...

Caterina Brindicci

immunology diseases – from conditions like asthma and COPD affecting millions across the globe, to rare diseases with limited treatment options. I ...

Symbicort granted paediatric exclusivity in the US

treatment of Chronic Obstructive Pulmonary Disease (COPD) in adults. NOTES TO EDITORS About Symbicort Symbicort is a combination formulation ...

H1 2019 Results

together with approvals for Breztri and Bevespi in COPD in Japan, illustrated further progress from our pipeline. Accompanying earnings growth this ...

AstraZeneca PLC fourth quarter and full year results 2014

Q3 2014 results: Duaklir Genuair: EU approval for COPD. Brodalumab2: superior to ustekinumab in second and third pivotal Phase III studies in ...

AstraZeneca Completes Acquisition Of Pearl Therapeutics

treatment for chronic obstructive pulmonary disease (COPD), currently in late-stage development, and inhaler and formulation technology that provides ...

Respiratory and Immunology

We are focused on chronic respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD), as well as immune-driven diseases ...

First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis with polyangiitis

anticipated 2021+ Chronic obstructive pulmonary disease (COPD) RESOLUTE: A phase III trial to evaluate the efficacy and safety of benralizumab in ...

AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next-generation respiratory inhalers

asthma and chronic obstructive pulmonary disease (COPD) need inhaled medicines2 and many make use of pressurised metered dose inhalers (pMDIs)2 which ...

Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next